Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00430183

Enrollment

788

Registered

2007-02-01

Start date

2007-05-08

Completion date

2030-10-31

Last updated

2023-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

stage I prostate cancer, stage IIB prostate cancer, stage IIA prostate cancer, stage III prostate cancer, adenocarcinoma of the prostate

Brief summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as goserelin and leuprolide, may stop the adrenal glands from making androgens. Giving docetaxel and leuprolide or goserelin before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known whether giving docetaxel and leuprolide or goserelin before surgery is more effective than surgery alone in treating patients with prostate cancer. PURPOSE: This randomized phase III trial is studying docetaxel and leuprolide or goserelin to see how well they work when given before surgery compared with surgery alone in treating patients with high-risk localized prostate cancer.

Detailed description

This randomized trial tests whether the addition of chemohormonal therapy improves PSA-progression free survival in patients with high risk, clinically-localized prostate cancer. The neoadjuvant approach is taken since there appears to be a higher acceptance rate in the prostate population for this type of therapy and several phase II trials have demonstrated its safety. Multiple chemotherapeutic therapies have shown efficacy in advanced prostate cancer and docetaxel has become the community standard. Many high risk patients are initiated on LHRH agonists at or near the time of diagnosis of their prostate cancer. In order to allow the inclusion of these patients in the protocol, enhanced enrollment and maintain compliance with therapy, up to 3 months of androgen deprivation therapy prior to enrollment will be permitted. This study will therefore be able to test the hypothesis that targeting both androgen-sensitive and chemotherapy- sensitive prostate cancer cells will improve outcomes in these high-risk patients. OUTLINE: This is a multicenter, randomized study. Patients are stratified according to nomogram-predicted biochemical progression-free survival at 5 years (0-20.9% vs 21-39.9% vs 40-59.9% vs ≥ 60%) and androgen-deprivation therapy prior to randomization ≤ 4 months (no vs yes). Patients are randomized to 1 of 2 treatment arms. Please see the Arms sections for more details. The primary and secondary objectives are described below. Primary: \- To determine whether treatment with neoadjuvant docetaxel and androgen deprivation therapy prior to radical prostatectomy will increase the rate of 3-year biochemical progression-free survival (bPFS) compared to treatment with immediate radical prostatectomy alone for high-risk prostate cancer patients. Secondary: * To compare the 5-year bPFS rate, bPFS, disease progression, disease-free survival, and overall survival of patients randomized to the two arms of this trial * To determine the safety and tolerability of neoadjuvant docetaxel and androgen deprivation therapy prior to surgery for high-risk patients undergoing radical prostatectomy * To compare the impact of neoadjuvant docetaxel and androgen deprivation therapy on time to clinically apparent local disease recurrence and metastatic disease in high-risk patients undergoing radical prostatectomy for clinically localized prostate cancer * To compare the impact of neoadjuvant docetaxel and androgen deprivation therapy relative to RP on pathologic tumor stage, frequency of lymph node metastases and positive margin rates for high-risk patients undergoing radical prostatectomy for clinically localized prostate cancer * To determine if changes in serum testosterone levels will predict bPFS * To determine prospectively whether PSA doubling time (PSADT) is a surrogate endpoint for time to clinical metastases and overall survival Patients are followed up to 15 years post-randomization.

Interventions

DRUGdocetaxel

75 mg/m\^2 will be administered intravenously over one hour on Day 1 of each cycle, every 21 days

DRUGLHRH agonist

Given intramuscularly

PROCEDUREsurgery

Patients undergo radical prostatectomy with staging pelvic lymphadenectomy.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Histologic documentation - Histologic documentation of prostatic adenocarcinoma. Patients with small cell, neuroendocrine, or transitional cell carcinomas are not eligible. All eligible patients must have a known Gleason sum based on biopsy or TURP at the time of registration. 2. Clinically localized disease - Patients must have clinical stage T1-T3a and no radiographic evidence of metastatic disease as demonstrated by: * EITHER CT or MRI of the abdomen and pelvis, OR endorectal MRI of the pelvis that demonstrate no nodes \> 1.5 cm. If one or more pelvic lymph node(s) measures \> 1.5 cm, a negative biopsy is required. If more than one lymph node is \> 1.5 cm, the largest or most accessible node should be biopsied. AND * Negative bone scan (with plain films and/or MRI and/or CT scan confirmation, if necessary). Positive PET and Prostascint scans are not considered proof of metastatic disease. 3. Determination of high-risk status: Patients must have either: * A Kattan nomogram predicted probability of being free from biochemical progression at 5 years after surgery of \< 60%. OR * Prostate biopsy Gleason sum ≥ 8 (NOTE: The Kattan nomogram probability must be calculated for all patients, including those eligible based on Gleason sum ≥ 8 only.) 4. Prior treatment - No prior treatment for prostate cancer including prior surgery (excluding TURP), pelvic lymph node dissection, radiation therapy, or chemotherapy. Patients may have received up to 4 months of androgen deprivation therapy (LHRH agonists, antiandrogens, or both) prior to being enrolled on the study. 5. Appropriate surgical candidates - Patients must be appropriate candidates for radical prostatectomy with an estimated life expectancy \> 10 years as determined by a urologist. Evidence of underlying cardiac disease should be evaluated prior to enrollment to ensure that patients are not at high risk of cardiac complications. 6. Clotting history - Patients with a history of deep venous thrombosis, pulmonary embolism, and/or cerebrovascular accident or currently requiring systemic anticoagulation are eligible provided they are determined to be candidates for radical prostatectomy. 7. ECOG performance status: 0-2 8. Age: ≥ 18 years of age 9. Required Initial Laboratory Values: * ANC ≥ 1500/μL * Platelet count ≥ 150,000/μL * Creatinine ≤ 2.0 mg/dL * Pre-registration serum PSA level ≤ 100 ng/mL * Bilirubin ≤ 1.5XULN (2.5XULN in patients with Gilbert's disease) * AST/ALT ≤1.5XULN

Design outcomes

Primary

Measure	Time frame	Description
Proportion of Biochemical Progression-Free Survival (bPFS Proportion) at 3 Years	Up to 3 years	Proportion of participants surviving 3 years from randomization without biochemical progression or death. bPFS was defined as the time from randomization to the date of the first documented biochemical progression or death. Progression will be defined as having experienced either of the following: a serum PSA level \> 0.2 ng/mL that increases on 2 consecutive occasions each of which is at least 3 months apart or death occurs. The time of biochemical failure is measured from the date of randomization to the date of the first PSA level \> 0.2 ng/mL.

Secondary

Measure	Time frame	Description
Time to Clinical Local Recurrence (The Time From Randomization to the First Biopsy-proven Recurrence in the Prostatic Bed or New Mass.)	Up to 15 years post-randomization	—
Time to Metastatic Disease Progression (The Date of Randomization to Date of Evidence of Systemic Disease on Bone Scan or Cross Sectional Imaging.)	Up to 15 years post-randomization	—
Unacceptable Toxicity (Grade 3 or Higher Toxicity)	Up to 15 years post-randomization	—
5-year bPFS Rate	5 years	Proportion of participants surviving 5 years from randomization without biochemical progression or death.
Disease Progression	Up to 15 years post-randomization	—
Overall Survival (The Date of Randomization to the Time of Death Due to Prostate Cancer.)	Up to 15 years post-randomization	—
Prostate Cancer-specific-free Survival (The Time From Randomization to the Time of Death Due to Prostate Cancer.)	Up to 15 years post-randomization	—

Countries

Canada, United States

Participant flow

Participants by arm

Arm	Count
Arm A: Docetaxel + LHRH Agonist + Surgical Intervention Patients receive six cycles of 75 mg/m\^2 docetaxel administered every 3 weeks combined with 18-24 weeks of androgen deprivation therapy. During each cycle of chemotherapy, all patients should undergo premedication with dexamethasone 8 mg orally prior to docetaxel. Dexamethasone may also be given intravenously according to institutional guidelines.\> \> Patients will also receive androgen deprivation for 18-24 weeks of an LHRH agonist (eg, leuprolide acetate, goserelin acetate). Additional premedication and antiemetics may be given at the physician's discretion and as defined by the protocol. \> \> Patients will undergo standard surgical intervention. The surgical procedures will be performed within 60 days of the completion of neoadjuvant therapy. Patients are allowed to receive adjuvant external beam radiation at the discretion of the treating physician and as defined per the protocol. It must be initiated within 6 months of the date of surgery.	391
Arm B: Surgical Intervention All patients undergo standard surgical intervention. The surgical procedures will be performed within 60 days of randomization. Patients are allowed to receive adjuvant external beam radiation at the discretion of the treating physician and as defined per the protocol. Adjuvant radiation must be initiated within 6 months of the date of surgery (surgery: Patients undergo radical prostatectomy with staging pelvic lymphadenectomy).	397
Total	788

Baseline characteristics

Characteristic	Arm A: Docetaxel + LHRH Agonist + Surgical Intervention	Arm B: Surgical Intervention	Total
Age, Continuous	62 years	63 years	63 years
Clinical stage by digital rectal examination (Primary Tumor (T) Stage) T1	102 Participants	129 Participants	231 Participants
Clinical stage by digital rectal examination (Primary Tumor (T) Stage) T2	219 Participants	204 Participants	423 Participants
Clinical stage by digital rectal examination (Primary Tumor (T) Stage) T3a	70 Participants	64 Participants	134 Participants
Race/Ethnicity, Customized Race Black	40 Participants	38 Participants	78 Participants
Race/Ethnicity, Customized Race Other	15 Participants	9 Participants	24 Participants
Race/Ethnicity, Customized Race Unknown	6 Participants	13 Participants	19 Participants
Race/Ethnicity, Customized Race White	330 Participants	337 Participants	667 Participants
Sex: Female, Male Female	0 Participants	0 Participants	0 Participants
Sex: Female, Male Male	391 Participants	397 Participants	788 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	39 / 391	54 / 397
other Total, other adverse events	361 / 391	0 / 0
serious Total, serious adverse events	31 / 391	0 / 0

Outcome results

Primary

Proportion of Biochemical Progression-Free Survival (bPFS Proportion) at 3 Years

Proportion of participants surviving 3 years from randomization without biochemical progression or death. bPFS was defined as the time from randomization to the date of the first documented biochemical progression or death. Progression will be defined as having experienced either of the following: a serum PSA level \> 0.2 ng/mL that increases on 2 consecutive occasions each of which is at least 3 months apart or death occurs. The time of biochemical failure is measured from the date of randomization to the date of the first PSA level \> 0.2 ng/mL.

Time frame: Up to 3 years

Arm	Measure	Value (NUMBER)
Arm A: Docetaxel + LHRH Agonist + Surgical Intervention	Proportion of Biochemical Progression-Free Survival (bPFS Proportion) at 3 Years	0.89 proportion of patients
Arm B: Surgical Intervention	Proportion of Biochemical Progression-Free Survival (bPFS Proportion) at 3 Years	0.84 proportion of patients

Secondary

5-year bPFS Rate

Proportion of participants surviving 5 years from randomization without biochemical progression or death.

Time frame: 5 years

Arm	Measure	Value (NUMBER)
Arm A: Docetaxel + LHRH Agonist + Surgical Intervention	5-year bPFS Rate	0.81 Proportion of participants
Arm B: Surgical Intervention	5-year bPFS Rate	0.74 Proportion of participants

Secondary